COMPOSITIONS COMPRISING TOPIRAMATE FOR TREATING DERMATOLOGICAL CONDITIONS
Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.
1 . A composition comprising topiramate and bioxome, redoxome, Hyaluronic acid (HA), extracellular vesicles (EV), or platelet rich derived (PRP) extracellular vesicles, or any combination thereof.
2 . The composition of claim 1 , comprising topiramate and a bioxome.
3 . The composition of claim 2 , wherein said topiramate is encapsulated by said bioxome.
4 . The composition of claim 1 , further comprising an excipient.
5 . The composition of claim 4 , wherein at least one excipient, or topiramate, or any combination thereof is encapsulated in said bioxome, in said redoxome, in said HA, in said extracellular vesicles (EV), or in said PRP extracellular vesicles.
6 . The composition of claim 1 , wherein said composition is formulated for topical delivery.
7 . The composition of claim 6 , further comprising an excipient selected from the group comprising: C12-C15 alkyl benzoate, mineral oil, glycerin, cetearyl alcohol, glyceryl stearate SE, dimethicone, steareth-2, steareth-21, aloe barbadensis leaf juice, panthenol, disodium EDTA, acrylates/C10-30 alkyl acrylate crosspolymer, tocopheryl acetate, retinyl palmitate, hydroxypropyl cyclodextrin, palmitoyl tripeptide 38, hydroxyethilcellulose, sodium hydroxide, phenoxyethanol, caprylyl glycol, or any combination thereof.
8 . The composition of claim 1 , further comprising an additional therapeutic agent for healing inflammatory condition of the skin.
9 . The compositions of claim 8 , wherein said additional therapeutic agent is selected from a group comprising Non Steroidal Anti Inflammatory Drugs (NSAIDs), antileukotrienes, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti TNFalpha drugs, or any combination thereof.
10 . A method for treating a dermatological condition comprising a step of administering to a subject in need thereof a composition comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof.
11 . The method of claim 10 , wherein said dermatological condition is an inflammatory condition.
12 . The method of claim 11 , wherein said inflammatory condition is a TNF mediated inflammatory disease, selected from skin aging or psoriasis.
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . The method of claim 10 , wherein said composition comprises topiramate and a bioxome.
17 . The method of claim 16 , wherein said topiramate is encapsulated by said bioxome.
18 . The method of claim 10 , wherein said composition further comprises an excipient.
19 . The method of claim 10 , wherein at least one excipient, or topiramate, or any combination thereof is encapsulated in said bioxome, in said redoxome, in said HA, in said extracellular vesicles (EV), or in said PRP extracellular vesicles.
20 . The method of claim 10 , wherein said composition is administered topically.
21 . The method of claim 20 , wherein said composition further comprising an excipient selected from the group comprising: C12-C15 alkyl benzoate, mineral oil, glycerin, cetearyl alcohol, glyceryl stearate SE, dimethicone, steareth-2, steareth-21, aloe barbadensis leaf juice, panthenol, disodium EDTA, acrylates/C10-30 alkyl acrylate crosspolymer, tocopheryl acetate, retinyl palmitate, hydroxypropyl cyclodextrin, palmitoyl tripeptide 38, hydroxyethilcellulose, sodium hydroxide, phenoxyethanol, caprylyl glycol, or any combination thereof.
22 . The method of claim 10 , wherein said composition further comprises an additional therapeutic agent.
23 . (canceled)
24 . The method of claim 22 wherein said additional therapeutic agent is selected from a group comprising Non Steroidal Anti Inflammatory Drugs (NSAIDs), antileukotrienes, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), anti TNFalpha drugs, or any combination thereof.